Home > Insider Trading > Filing (0001104659-13-023060)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1396814	Pacira Pharmaceuticals Inc.	PCRX	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1232258	Ltd Cayman Bioventures Hbm	Centennial Towers, 3Rd Floor 2454 West Bay Road Grand Cayman E9		No	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Disposition	2013-03-11	500,000	$27.86	2,933,993	No	4	S	Direct
Common Stock	Disposition	2013-03-18	400,000	$28.19	2,533,993	No	4	S	Direct
Common Stock	Disposition	2013-03-19	9,100	$27.86	2,524,893	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	3,433,993	Direct

Footnotes

This number reflects the correction of the total holdings of the reporting person which was incorrectly reported on the reporting person's original Form 3 and two subsequent Form 4 filings.
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 15, 2013.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.775 to $28.75 inclusive. Upon request, the reporting person undertakes to provide the Issuer, any security holder of the issuer, or the Securities and Exchange Commission, full information regarding the shares sold at each separate price within the ranges set forth in footnote three (3) of this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.50 to $28.11 inclusive. Upon request, the reporting person undertakes to provide the Issuer, any security holder of the issuer, or the Securities and Exchange Commission, full information regarding the shares sold at each separate price within the ranges set forth in footnote four (4) of this Form 4.